Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art
Heart Failure (HF) is a cardiovascular condition with high morbidity and mortality that conditions one of the most critical problems in public health. Despite advances in recent decades, patients continue to have major cardiovascular events and marked reduction in their quality of life. Sodium-Gluco...
Main Authors: | Yilmar Alexader Meza-González, Natalia Alfonso-Arrieta, Stephany Salas-Solorzano, Victor Florez-Garcia |
---|---|
Format: | Article |
Language: | English |
Published: |
Emergency Department of Hospital San Pedro (Logroño, Spain)
2023-02-01
|
Series: | Iberoamerican Journal of Medicine |
Subjects: | |
Online Access: | https://doi.org/10.53986/ibjm.2023.0009 |
Similar Items
-
Mechanisms and clinical significance of nephroprotective action of sodium-glucose cotransporter 2 inhibitors
by: I. Y. Pchelin, et al.
Published: (2019-01-01) -
Sodium glucose co-transporter 2 inhibitors in heart failure therapy
by: Yüksel Çavuşoğlu, et al.
Published: (2020-04-01) -
SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018-02-01) -
Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
by: O. Y. Sukhareva, et al.
Published: (2022-02-01) -
Nephroprotection by SGLT2 Inhibition: Back to the Future?
by: Luca De Nicola, et al.
Published: (2020-07-01)